Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clascoterone Cream 1% for Sebum Reduction in Acne
NCT06415279Phase 4Completed
- Sponsor
- Sun Pharma
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clascoterone in acne vulgaris, sponsored by Sun Pharma. Primary endpoint: Change in Causal Sebum Measurements at 16 weeks. Started Feb 2024; status: completed.
02
Drugs
clascoterone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06415279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415279.